Drug Profile


Alternative Names: GLS4; Morphothiadin; Morphothiadine mesilate; Morphothiadine mesylate

Latest Information Update: 26 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator HEC Pharm
  • Class Antivirals; Mesylates
  • Mechanism of Action Hepatitis B virus replication inhibitors; Viral core protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Hepatitis B

Most Recent Events

  • 25 Aug 2016 Phase-II/III clinical trials in Hepatitis B in China (PO) (HEC Pharm pipeline, August 2016)
  • 11 Jan 2016 Phase-II development is ongoing in China
  • 30 Dec 2015 Phase-I clinical trials in Hepatitis B (Combination therapy) in China (PO) (ChiCTR-IIR-16008284)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top